JP2009535390A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535390A5
JP2009535390A5 JP2009508465A JP2009508465A JP2009535390A5 JP 2009535390 A5 JP2009535390 A5 JP 2009535390A5 JP 2009508465 A JP2009508465 A JP 2009508465A JP 2009508465 A JP2009508465 A JP 2009508465A JP 2009535390 A5 JP2009535390 A5 JP 2009535390A5
Authority
JP
Japan
Prior art keywords
acid
thieno
pyrimidin
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009508465A
Other languages
English (en)
Japanese (ja)
Other versions
JP5329395B2 (ja
JP2009535390A (ja
Filing date
Publication date
Priority claimed from GBGB0608820.7A external-priority patent/GB0608820D0/en
Application filed filed Critical
Publication of JP2009535390A publication Critical patent/JP2009535390A/ja
Publication of JP2009535390A5 publication Critical patent/JP2009535390A5/ja
Application granted granted Critical
Publication of JP5329395B2 publication Critical patent/JP5329395B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009508465A 2006-05-04 2007-05-04 医薬化合物 Expired - Fee Related JP5329395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0608820.7A GB0608820D0 (en) 2006-05-04 2006-05-04 Pharmaceutical compounds
GB0608820.7 2006-05-04
PCT/GB2007/001644 WO2007132171A1 (en) 2006-05-04 2007-05-04 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2009535390A JP2009535390A (ja) 2009-10-01
JP2009535390A5 true JP2009535390A5 (enExample) 2010-06-24
JP5329395B2 JP5329395B2 (ja) 2013-10-30

Family

ID=36603916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508465A Expired - Fee Related JP5329395B2 (ja) 2006-05-04 2007-05-04 医薬化合物

Country Status (8)

Country Link
US (1) US8153639B2 (enExample)
EP (1) EP2035431B1 (enExample)
JP (1) JP5329395B2 (enExample)
CN (1) CN101479276B (enExample)
CA (1) CA2651136C (enExample)
ES (1) ES2562935T3 (enExample)
GB (1) GB0608820D0 (enExample)
WO (1) WO2007132171A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
AR064154A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
WO2009013348A2 (en) * 2007-07-26 2009-01-29 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
ES2566339T3 (es) * 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
UA101676C2 (uk) 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US8785651B2 (en) 2009-03-24 2014-07-22 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
CN102459253B (zh) 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
WO2010136491A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
EP2456443A1 (en) * 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
MX2012005463A (es) 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
KR101447789B1 (ko) 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2015043398A1 (zh) * 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
AR045445A1 (es) 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2009535390A5 (enExample)
CN114163457B (zh) 嘧啶并五元氮杂环化合物及其用途
JP7215687B2 (ja) キナーゼ阻害活性を有する化合物、その製造方法及び用途
AU2006249847B2 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
JP6511430B2 (ja) がんの治療のための化合物および組成物
RU2008145663A (ru) Производное тиено[3,2-d]пиримидина в качестве ингибитора фосфатидилинозитол-3-киназы (рi3к)
CN112390814B (zh) Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
JP2011521968A5 (enExample)
CN102225926A (zh) 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
TW202521549A (zh) 一種稠環化合物及在ｋｒａｓ抑制劑方面的應用
WO2021017880A1 (zh) 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用
WO2016208592A1 (ja) 二環性複素環アミド誘導体
CN115697987B (zh) 雌激素受体调节剂化合物及其用途
TW201829396A (zh) 嘧啶化合物及包括其的藥學組成物
TW201321371A (zh) 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
JP6239149B2 (ja) 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
BR112016005606B1 (pt) Composto, composição farmacêutica, e usos de um composto
CN113004285B (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
CN114341135B (zh) 雌激素相关受体α(ERRα)调节剂
JP6564394B2 (ja) 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用
CN108299420B (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
CN114105977B (zh) 雌激素受体调节剂化合物及其用途
CN104140395B (zh) 丁炔酰胺衍生物及其制法和药物组合物与用途
JP7776418B2 (ja) イソクエン酸デヒドロゲナーゼ（ｉｄｈ）阻害剤